Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuro-immunology
•
General Neurology
How can we minimize the risk of overinterpreting reactive findings from repeat lumbar punctures?
e.g. reactive pleiocytosis, in light of publication from
Schimdauer et al in Eur J Neurol 2025 Apr
Related Questions
When do you offer high-dose vitamin D for patients with multiple sclerosis with normal serum levels?
What biomarkers best predict the response to B-cell depleting therapies in MS?
How do you handle medication management for patients on immunosuppressive therapy who are lost to follow-up?
Do you consider steroid-sparing agents for treatment of patients with steroid responsive relapsed Hashimoto Encephalopathy?
What criteria do you use to differentiate between MOGAD and MS in pediatric patients?
What is the role of skin biopsy for evaluating small fiber neuropathy in patients with rheumatic disease who have treatment recalcitrant pain?
When do you consider pembrolizumab for the treatment of progressive multifocal leukoencephalopathy?
What are your vaccine recommendations while patients are on biologics?
In a patient with strong serologic evidence of SLE presenting with isolated bilateral lower limb sensorimotor neuropathy, normal neuroimaging, and CSF, would you initiate cyclophosphamide with pulse-dose steroids upfront, or reserve escalation (e.g., plasma exchange or immunosuppressants) for cases refractory to steroids?
Would you proceed with anti-CD20 treatment in an MS patient who is VZV IgG negative in spite of vaccination in the last year?